Navigation Links
Clinical trial advances new approach to re-sensitizing breast cancer
Date:12/11/2009

San Antonio, Tex. A new drug cocktail might be the right mix to fight breast cancer after it becomes resistant to standard therapy. Details of a new study supporting this approach suggest it's possible to re-sensitize tumors thus allowing treatments to work again. The findings were presented today at the CTRC-AACR San Antonio Breast Cancer Symposium.

The study involves post-menopausal women whose advanced breast cancers are fueled by estrogen, often called estrogen-receptor or progesterone-receptor positive cancers. The standard treatment is anti-hormonal medicines, such as aromatase inhibitors (AIs), which lower the amount of estrogen in the body. Over time, however, the cancer figures out a way to thrive without the estrogen. The treatment strategy under investigation to fight this resistance combines an aromatase inhibitor with sorafenib, an oral medication FDA-approved to treat liver and kidney cancers.

"We believe the sorafenib might disrupt the machinery created by the tumor to grow without the estrogen," says Claudine Isaacs, MD, clinical director of breast cancer program at Georgetown Lombardi Comprehensive Cancer Center and presenting author of the study. "After the machinery is destroyed, the aromotase inhibitor can do its work again. We're already seeing some encouraging responses to this approach."

The multi-center, phase II study involves 35 post-menopausal women with metastatic breast cancer resistant to aromotase inhibitors. The women continue taking an aromotase inhibitor for the study, but they also take sorafenib. The analysis presented today demonstrates a clinical benefit rate in 20 percent of the women. Clinical benefit means the patient has a complete or partial response and includes those who have stable disease for at least 6 months (24 weeks).

Isaacs says this finding suggests that sorafenib is acting to reverse resistance to AIs as this type of response would not have been expected with either sorafenib alone or with continuing the AI.

"To manage breast cancer long term, it's apparent that we may need to continually switch drugs to keep up with how a cancer evolves and evades each approach," Isaacs concludes.

Isaacs says side-effects were common but most were mild or were managed by reducing the dose. Such side effects included redness and irritation of the palms and soles, skin rash, fatigue, nausea/vomiting and diarrhea. Serious hypertension occurred in about 11 percent of the patients. Isaacs says this factor was more easily managed if blood pressure was brought under good control before patients were administered the combination.


'/>"/>

Contact: Karen Mallet
km463@georgetown.edu
215-514-9751
Georgetown University Medical Center
Source:Eurekalert

Related medicine news :

1. HealthWyse Clinical and Financial Point of Care Software Addresses OASIS-C Regulations and More
2. Drug Information Association (DIA) Announces New Clinical Safety and Pharmacovigilance Certificate Program
3. Most Antidepressants Miss Key Target of Clinical Depression
4. Quantros(TM) Unveils Clinical Cafe, Social Networking Website for Healthcare Professionals Focused on Safety, Quality and Compliance
5. Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting
6. Reportlinker Adds Emerging Clinical Trial Locations - India: Market Dynamics and the Changing Healthcare and Regulatory Environment
7. UM Clinical Research Building awarded prestigious LEED Building Certification
8. OrbusNeich Announces First Patient Enrolled in REMEDEE, a Randomized Clinical Trial of the Combo Bio-engineered Sirolimus Eluting Stent
9. Elsevier Launches New Online ARRA Resource Center and Clinical Decision Support Blog
10. Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines
11. Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... 2017 , ... Young Asset Protection, an insurance provider and ... greater Pittsburgh metropolitan region, is joining forces with the local chapter of the ... , Variety the Children’s Charity is a national organization dedicated to empowering, enabling, ...
(Date:4/21/2017)... ... April 21, 2017 , ... The Hong Kong Polytechnic University (PolyU) ... facility among higher education institutions in Hong Kong to support teaching, learning and research. ... range and quantity of facilities in Hong Kong. , With an area of ...
(Date:4/21/2017)... CA (PRWEB) , ... April 21, 2017 , ... ... Joseph Health held the much anticipated Regional Primary Care Spring Symposium on April ... in the local medical community, offering physicians and healthcare providers an opportunity to ...
(Date:4/21/2017)... CA (PRWEB) , ... April 21, 2017 , ... ... to experienced, personalized dental care since 1985. After thirty-two years, Dr. Latner has become ... privilege to help my numerous clients over the years with all their dental needs,” ...
(Date:4/21/2017)... , ... April 21, 2017 , ... ... Detroit reveals good news for older shoulder replacement patients; post-operative recovery just might ... from two groups of patients presenting with osteoarthritis following surgery: 262 patients under ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 2017 Research and Markets has announced the ... by Rapidly Expanding Injectables Market and Increasing Usage of Complex Biologics ... ... will rise from USD 20 Billion in 2015 to around USD ... Technologies - Innovation Driven by Rapidly Expanding Injectables Market and Increasing ...
(Date:4/20/2017)... 2017 Eyevensys, a private biotechnology ... gene expression technology that enables the safe, local, sustained ... a wide range of ophthalmic diseases, announces it has ... Regulatory Agency (MHRA) to advance its technology into clinical ... The ...
(Date:4/19/2017)... The Mobile X-Ray product segment is the most ... the forecast period Mobile X-Ray segment is the ... X-Ray devices market, which is estimated to be valued at ... CAGR of 7% over the forecast period. Mobile X-Ray segment ... US$ 100 Mn in 2017 over 2016. The segment,s revenue ...
Breaking Medicine Technology: